Cartesian Therapeutics/$RNAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Ticker
$RNAC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
66
ISIN
US8162123025
RNAC Metrics
BasicAdvanced
$260M
-
-$1.73
-
-
Price and volume
Market cap
$260M
52-week high
$29.65
52-week low
$8.46
Average daily volume
70K
Financial strength
Current ratio
12.343
Quick ratio
12.148
Long term debt to equity
-47.556
Total debt to equity
-64.556
Profitability
EBITDA (TTM)
-41.935
Gross margin (TTM)
-46.43%
Net profit margin (TTM)
-112.11%
Operating margin (TTM)
-129.81%
Effective tax rate (TTM)
-0.75%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-7.50%
Return on equity (TTM)
55.29%
Valuation
Price to revenue (TTM)
6.555
Price to book
-11.9
Price to tangible book (TTM)
-1.18
Price to free cash flow (TTM)
-5.54
Free cash flow yield (TTM)
-18.05%
Free cash flow per share (TTM)
-180.50%
Growth
Revenue change (TTM)
31.91%
Earnings per share change (TTM)
-96.90%
What the Analysts think about RNAC
Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.
RNAC Financial Performance
Revenues and expenses
RNAC Earnings Performance
Company profitability
RNAC News
AllArticlesVideos
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewsWire·2 weeks ago
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
GlobeNewsWire·3 weeks ago
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cartesian Therapeutics stock?
Cartesian Therapeutics (RNAC) has a market cap of $260M as of June 20, 2025.
What is the P/E ratio for Cartesian Therapeutics stock?
The price to earnings (P/E) ratio for Cartesian Therapeutics (RNAC) stock is 0 as of June 20, 2025.
Does Cartesian Therapeutics stock pay dividends?
No, Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Cartesian Therapeutics dividend payment date?
Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) does not currently have a Beta indicator.